Clinical Trial: A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)

U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07787650) titled 'A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)' on Aug. 24.

Brief Summary: The primary purpose of this study is to evaluate the safety and tolerability profile of S-606001 in participants with LOPD.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Pompe Disease

Intervention: DRUG: S-606001

S-606001 will be administered orally as a tablet.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shionogi

Disclaimer: Curated by HT Syndication....